H.C. Wainwright raised the firm’s price target on Enliven (ELVN) to $40 from $39 and keeps a Buy rating on the shares following the Q1 report.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ELVN:
- Enliven Therapeutics: Strategic Focus and Promising Developments Justify Buy Rating
- Positive Buy Rating for Enliven Therapeutics Driven by Promising Phase 1 Results of ELVN-001 in CML
- Enliven announces updated myeloid leukemia data from Phase 1 study
- Promising Efficacy and Safety Data from Enliven Therapeutics’ ELVN-001 Trial Supports Buy Rating
- JonesResearch sees ‘clear buying opportunity” in Enliven